Bevacizumab News and Research

RSS

Bevacizumab is a recombinant humanized monoclonal antibody directed against the vascular endothelial growth factor (VEGF), a pro-angiogenic cytokine. Bevacizumab binds to VEGF and inhibits VEGF receptor binding, thereby preventing the growth and maintenance of tumor blood vessels.

Leveraging cancer therapies to combat tuberculosis

What could cancer teach us about tuberculosis? That's a question Meenal Datta has been chasing since she was a graduate student.

25 Mar 2024

Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth

Breakthrough in Brain Cancer Treatment: Dual-Target CAR T Cell Therapy Shows Promise in Early Clinical Trial.

15 Mar 2024

Study paves the way for improving personalized treatment of patients with glioblastoma

A study led by the ITACA Institute of the Universitat Politècnica de València, with the participation of the Institut Català d'Oncologia (ICO), the Institut Investigació Germans Trias I Pujol (IGTP) and the Hospital Clinic de Barcelona, opens up a novel approach for improving personalized treatments for patients with glioblastoma, one of the most aggressive types of cancer in existence today.

31 Jan 2024

Children with neuroblastomas may benefit from new drug cocktail

Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumor drugs as well as chemotherapy, a new trial has found.

9 Jan 2024

Tumor debulking does not impact quality of life in metastatic colorectal cancer, study finds

New research in the October 2023 issue of JNCCN-;Journal of the National Comprehensive Cancer Network finds that intensive local-regional treatment to remove as much tumor as possible (known as "debulking"), in addition to standard systemic therapy, does not impact overall quality of life significantly for people with metastatic colorectal cancer.

13 Oct 2023

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

21 Sep 2023

The role of diet in the management of retinal vein occlusion

Researchers investigate the potential impact of dietary habits on retinal vein occlusion.

27 Jul 2023

The potential prognostic role of AhRR and PPP1R3C expression in serous ovarian cancer

Study evaluated genes with copy number alterations to identify biomarkers for ovarian cancer prognosis.

18 Jul 2023

Mays Cancer Center conducts clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma

The Mays Cancer Center at The University of Texas Health Science Center at San Antonio recently conducted a clinical trial combining two drugs in patients with recurrent, high-grade glioblastoma (GBM).

24 May 2023

Study finds socio-economic inequalities in access to novel therapies for many NSCLC patients

Novel anti-cancer therapies were not accessible to more than half of the patients in England who were diagnosed with non-small cell lung cancer, according to a new study published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

19 May 2023

Correcting abnormalities in solid tumor's blood vessels can improve efficacy of CAR-T cell therapy

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited efficacy against glioblastoma-;the deadliest type of primary brain cancer-;and other solid tumors.

14 Mar 2023

Pembrolizumab offers major added survival benefit for patients with advanced cervical cancer

Pembrolizumab has recently been approved in combination with chemotherapy for the treatment of women with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1. Chemotherapy with or without bevacizumab is possible.

25 Jan 2023

Plasma GH is a biomarker candidate for predicting outcomes in advanced HCC patients treated with Atezo/Bev

A new research paper was published in Oncotarget's Volume 13 on December 6, 2022, entitled, "Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients."

22 Dec 2022

Study compares the performance of two most popular AMD drugs

A pilot, "look-back" study of information about 106 patients with "wet" age-related macular degeneration (AMD) treated at the Wilmer Eye Institute at Johns Hopkins Medicine has revealed that nearly half of patients treated with aflibercept could safely stop eye injection therapy after one year without further vision loss.

30 Nov 2022

Researchers highlight the importance of localizing BRCA gene mutations for better ovarian cancer treatment

Mutations of BRCA1 and BRCA2 genes, which are inherited by 1 in 400 and 1 in 800 people respectively, significantly increase the risk of certain cancers such as ovarian, breast, pancreatic and prostate cancer.

28 Nov 2022

Combination of three existing drugs extends survival in mouse models of lethal brain cancer

A Ludwig Cancer Research study has identified a combination of three existing drugs that significantly extends survival in mouse models of the lethal brain cancer glioblastoma multiforme (GBM).

20 Sep 2022

A stepped regimen of anti-VEFG drugs leads to good vision outcomes in diabetic macular edema

Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular edema start with a less expensive medicine and switch to a more expensive medicine if vision does not improve sufficiently, gives results similar to starting off with the higher-priced drug.

14 Jul 2022

Researchers identify substantial lack of racial and ethnic data in studies of rare genetic disorder

In a review of published research papers, investigators from the Johns Hopkins Medicine Hereditary Hemorrhagic Telangiectasia Center have identified a substantial lack of racial and ethnic data that may be negatively impacting the treatment and diagnosis of this rare disorder in diverse patients.

11 Jul 2022

Combination of three technologies makes potential treatment effective against aggressive brain tumor

A drug carrier able to reach the brain, bind to an aggressive type of tumor called glioblastoma multiforme, and release a chemotherapeutic agent has been tested for the first time by Brazilian researchers.

15 Jun 2022

Black, Hispanic patients with advanced liver cancer have lower chance of receiving immunotherapy

Racial and ethnic minorities diagnosed with advanced liver cancer have a lower chance of receiving immunotherapy, the most effective treatment for patients with the disease, according to a new study led by Cedars-Sinai Cancer investigators.

8 Jun 2022